The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Renvela

800 milligram(s) Tablet

Genzyme Europe B.V.EU/1/09/521/1-3

Main Information

Trade NameRenvela
Active SubstancesSevelamer carbonate
Strength800 milligram(s)
Dosage FormTablet
Licence HolderGenzyme Europe B.V.
Licence NumberEU/1/09/521/1-3

Group Information

ATC CodeV03AE Drugs for treatment of hyperkalemia and hyperphosphatemia
V03AE02 sevelamer

Status

Authorised/WithdrawnAuthorised
Licence Issued10/06/2009
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing Status

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back